Beigene Company Profile

Aggregated data from the web about Beigene

Company Name	Beigene
Website	beigene.com
Snippet	BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019.
Type	Public
Founded	2010
Founder	Xiaodong Wang, John V. Oyler
Revenue	$309 million (2020) [2] $428 million (2019)[2]
Website	beigene.com
Traded as	Nasdaq: BGNE, SEHK: 6160
Headquarters	Beijing, China, and Cambridge, Massachusetts, U.S.[1]
Operating income	$–1.658 billion (2020)[3]$–960 million (2019)[3]

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.